Sanofi SA (SNY) on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of Cenrifki for treating secondary progressive multiple sclerosis (SPMS) in patients without relapses in the past two years.
A final decision from the agency is expected in the coming months.
The positive opinion is based on data from the HERCULES Phase 3 study in non-relapsing SPMS, supported by findings from the GEMINI 1 and GEMINI 2 Phase 3 studies in relapsing multiple sclerosis.
Sanofi said additional regulatory submissions for Cenrifki are currently under review in multiple countries worldwide.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.